EE03826B1 - Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode - Google Patents

Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode

Info

Publication number
EE03826B1
EE03826B1 EE9700253A EE9700253A EE03826B1 EE 03826 B1 EE03826 B1 EE 03826B1 EE 9700253 A EE9700253 A EE 9700253A EE 9700253 A EE9700253 A EE 9700253A EE 03826 B1 EE03826 B1 EE 03826B1
Authority
EE
Estonia
Prior art keywords
preparation
compound
combination
pharmaceutical composition
product containing
Prior art date
Application number
EE9700253A
Other languages
English (en)
Estonian (et)
Other versions
EE9700253A (et
Inventor
Joseph Kukla Michael
Adriaan Jan Janssen Paul
Emiel Lodewijk Moereels Henri
William Ludovici Donald
Heeres Jan
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9700253A publication Critical patent/EE9700253A/xx
Publication of EE03826B1 publication Critical patent/EE03826B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
EE9700253A 1996-10-01 1997-09-26 Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode EE03826B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2726096P 1996-10-01 1996-10-01

Publications (2)

Publication Number Publication Date
EE9700253A EE9700253A (et) 1998-04-15
EE03826B1 true EE03826B1 (et) 2002-08-15

Family

ID=21836641

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700253A EE03826B1 (et) 1996-10-01 1997-09-26 Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode

Country Status (34)

Country Link
US (4) US6380194B1 (no)
EP (1) EP0834507B1 (no)
JP (1) JP4127882B2 (no)
KR (1) KR100478846B1 (no)
CN (1) CN1083438C (no)
AP (1) AP914A (no)
AR (1) AR008864A1 (no)
AT (1) ATE267179T1 (no)
AU (1) AU740809B2 (no)
BR (1) BR9704937A (no)
CA (1) CA2216486A1 (no)
CZ (1) CZ297333B6 (no)
DE (1) DE69729153T2 (no)
DK (1) DK0834507T3 (no)
EE (1) EE03826B1 (no)
ES (1) ES2221679T3 (no)
HK (1) HK1009676A1 (no)
HR (1) HRP970526B1 (no)
HU (1) HU225270B1 (no)
ID (1) ID19599A (no)
IL (1) IL121849A (no)
MY (1) MY123803A (no)
NO (1) NO311614B1 (no)
NZ (1) NZ328854A (no)
OA (1) OA10620A (no)
PL (1) PL190155B1 (no)
PT (1) PT834507E (no)
RU (1) RU2186774C2 (no)
SG (1) SG53075A1 (no)
SI (1) SI0834507T1 (no)
SK (1) SK285241B6 (no)
TR (1) TR199701070A2 (no)
TW (1) TW411335B (no)
ZA (1) ZA978766B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
SI1129079T1 (sl) * 1998-11-10 2006-06-30 Janssen Pharmaceutica Nv 2,4-disubstituirani triazinski derivati z anti-HIV aktivnostjo
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
AU2735201A (en) * 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
CA2451125A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
NZ531853A (en) 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
AU2002363174B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
EP1509515A4 (en) 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
AU2003241482A1 (en) * 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004074266A1 (en) 2003-02-07 2004-09-02 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
WO2006024175A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. 2,4,6-TRIAMINO-S-TRIAZINE-BASED COMPOUNDS WHICH BIND TO THE TAIL (Fc) PORTION OF IMMUNOGLOBULINS AND THEIR USE
TW200626561A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-substituted pyrimidines
TW200626560A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
TW200626574A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
RU2403254C2 (ru) 2004-10-29 2010-11-10 Тиботек Фармасьютикалз Лтд. Бициклические производные пиримидина, ингибирующие вич
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
CA2923637C (en) * 2006-12-29 2018-10-02 Janssen Sciences Ireland Uc Hiv inhibiting 5,6-substituted pyrimidines
CN101573343B (zh) 2006-12-29 2016-02-24 爱尔兰詹森科学公司 抑制人免疫缺陷病毒的6-取代的嘧啶
WO2008131547A1 (en) * 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
US8372849B2 (en) * 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US9058223B2 (en) * 2011-04-22 2015-06-16 Microsoft Technology Licensing Llc Parallel entropy encoding on GPU
US9549558B2 (en) * 2012-10-24 2017-01-24 Basf Se Herbicidal azines
CN106458937A (zh) * 2014-04-11 2017-02-22 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE226474C (no)
US2309663A (en) * 1943-01-26 Process fok preparing substituted
US2817814A (en) 1953-08-13 1957-12-24 Gen Electric Corona detection probe
GB771327A (en) 1953-10-26 1957-03-27 Monsanto Chemicals Production of heat hardenable melamine-formaldehyde condensation products
US2817614A (en) * 1953-10-26 1957-12-24 Monsanto Chemicals Internally plasticized melamine resins and laminates made therewith
JPS4927592B1 (no) * 1970-05-13 1974-07-18
GB1390235A (en) 1971-08-07 1975-04-09 Kakenyaku Kako Kk 2-amino-4,6substituted-s triazines and methods for their preparation
DE3724379A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Verfahren zur herstellung feinteiliger magnetischer hexaferritpigmente
WO1993010116A1 (en) * 1991-11-12 1993-05-27 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater

Also Published As

Publication number Publication date
EE9700253A (et) 1998-04-15
US20020147181A1 (en) 2002-10-10
BR9704937A (pt) 2000-06-06
RU2186774C2 (ru) 2002-08-10
ID19599A (id) 1998-07-23
SI0834507T1 (en) 2004-10-31
MY123803A (en) 2006-06-30
TR199701070A2 (xx) 1998-04-21
KR19980032428A (ko) 1998-07-25
DE69729153T2 (de) 2005-01-27
CN1180698A (zh) 1998-05-06
ES2221679T3 (es) 2005-01-01
ZA978766B (en) 1999-03-30
AP9701109A0 (en) 1997-10-31
TW411335B (en) 2000-11-11
MX9707511A (es) 1998-06-30
AP914A (en) 2000-12-18
SK285241B6 (sk) 2006-09-07
US6858609B2 (en) 2005-02-22
HUP9701596A2 (hu) 1999-06-28
KR100478846B1 (ko) 2006-06-13
PT834507E (pt) 2004-10-29
HRP970526B1 (en) 2002-10-31
OA10620A (en) 2002-09-03
US7449575B2 (en) 2008-11-11
NO974368L (no) 1998-04-02
EP0834507B1 (en) 2004-05-19
AU740809B2 (en) 2001-11-15
JP4127882B2 (ja) 2008-07-30
AR008864A1 (es) 2000-02-23
IL121849A0 (en) 1998-02-22
NZ328854A (en) 2000-10-27
SG53075A1 (en) 1998-09-28
CZ299397A3 (cs) 1998-11-11
EP0834507A1 (en) 1998-04-08
NO311614B1 (no) 2001-12-17
PL190155B1 (pl) 2005-11-30
HUP9701596A3 (en) 2000-04-28
HRP970526A2 (en) 1998-10-31
PL322369A1 (en) 1998-04-14
HU9701596D0 (en) 1997-11-28
HU225270B1 (en) 2006-08-28
US20060189614A1 (en) 2006-08-24
SK131997A3 (en) 1999-06-11
CA2216486A1 (en) 1998-04-01
DK0834507T3 (da) 2004-09-06
US6962916B2 (en) 2005-11-08
US6380194B1 (en) 2002-04-30
NO974368D0 (no) 1997-09-22
IL121849A (en) 2001-08-26
DE69729153D1 (de) 2004-06-24
HK1009676A1 (en) 1999-06-04
US20030199473A1 (en) 2003-10-23
ATE267179T1 (de) 2004-06-15
AU3926697A (en) 1998-04-09
CZ297333B6 (cs) 2006-11-15
JPH10114759A (ja) 1998-05-06
CN1083438C (zh) 2002-04-24

Similar Documents

Publication Publication Date Title
EE03826B1 (et) Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
SI1156049T1 (en) Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
FI964473A (fi) Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II)
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
ZA968945B (en) 1,3-Dihydro-indol-2-one derivatives process for their preparation and the pharmaceutical compositions containing them
SI0780390T1 (en) Crystalline modification of CDCH, process for its preparation and pharmaceutical compositions containing it
HUP9601033A3 (en) Benzofurane derivatives, process for their preparation, use of them as intermediate and pharmaceutical compositions containing the compounds
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
HUP9901326A3 (en) Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
CZ346595A3 (en) Substituted derivatives of 4-phenylthiazoles, process of their preparation and pharmaceutical compositions containing thereof
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
EE200200326A (et) Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
HUP9801879A3 (en) Pyridazinone-derivatives as endothelin-receptor antagonists, use thereof, pharmaceutical compositions containing these compounds and process for the preparation of the compounds and the compositions
EE04778B1 (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200100253A (et) 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE03773B1 (et) Kondenseeritud imidasoolderivaadid, nende kasutamine ravimina, neid sisaldav farmatseutiline kompositsioon, meetod selle valmistamiseks ning seda sisaldav kombineeritud preparaat
HUP9602324A3 (en) Piperidinyl-methyl-oxazolidinon derivatives, pharmaceutical compositions containing the same, process for the preparation of the compounds and use of them
HUP9601712A3 (en) Substituted benzothiazine derivatives, intermediates of them, process for their preparation and pharmaceutical compositions containing the same
HUP0000854A3 (en) 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine derivatives, pharmaceutical compositions containing them and process for the preparation of both
HU901569D0 (en) Process for the preparation of triazine derivatives and pharmaceutical compositions containing such compounds
EE04155B1 (et) 2,4,4-triasendatud-1,3-dioksolaanid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, kombinatsioon ja produkt

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20070926